The FDA has set a PDUFA target action date of October 23, 2025, for the low-dose atropine formulation.

Additionally, the prognosis of macular edema may help clinicians evaluate renal function, investigators reported ...

Urcosmid is a lipid conjugated chemerin peptide agonist of the ChemR23 G-protein coupled receptor, typically found on immune ...

RPESC-RPE-4W is a proprietary retinal pigment epithelium cell therapy for patients with dry age-related macular degeneration.

Insights shed light on what the approval means for providers and their patients affected by this neurodegenerative retinal ...

D-150 is a potential backbone therapy that is designed to provide multi-year sustained delivery of anti-VEGF (aflibercept and ...

The US Food and Drug Administration (FDA) has approved revakinagene taroretcel-lwey (ENCELTO) from Neurotech Pharmaceuticals ...

In addition to comparable BCVA levels, the researchers concluded that the PDS implant “provides effective, durable, and ...

The findings were from 6 patients in the first low-dose cohort of the ongoing first-in-human trial (NCT04627428).

Physicians’ Education Resource (PER) has launched Retina Resource, a comprehensive source of education and information on the ...

Researchers set out to determine the age groups for which a polygenic risk score would most effectively predict glaucomatous ...

To tackle systemic barriers to eye care, the organization is co-hosting an event titled “No Woman Left Behind – Advancing Eye ...